SOURCE: InoLife Technologies, Inc.

January 05, 2011 08:30 ET

InoLife Technologies Launches DNA Predisposition Testing Product at the Anti-Aging and Biomedical Technologies Convention in Las Vegas

Test Reveals Genetic Predisposition for 25 Diseases and Conditions

RALEIGH, NC--(Marketwire - January 5, 2011) - InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announces today the introduction of its DNA Predisposition Testing Product revealed at the A4M Anti-Aging and Biomedical Technologies Convention exhibited in Las Vegas on December 9-11, 2010.

The test is designed to look into your DNA and identify key markers that, if present, may indicate an increased chance for you to develop certain serious diseases. By ordering and completing this test, your physician or medical practitioner will be able to determine if you are genetically predisposed to 25 diseases and conditions in categories such as cardiovascular conditions, cancers, immune disorders and other general health conditions. Some of the most common diseases and conditions covered by this test include heart disease, breast cancer, Alzheimer, types 1 & 2 diabetes and even your propensity for obesity. Please refer to our website http://www.inolifetech.com/Predisposition-Test.htm for a list of the diseases that can be identified.

InoLife's DNA Predisposition Test is evaluated by only highly accredited testing laboratories. Upon the laboratory's examination of your DNA, a personalized report will be created for your physician's or medical practitioner's review. In your report each condition will be ranked according to your lifetime risk, and will be qualified as high, medium or low risk. The markers for conditions included in the report from the laboratories InoLife uses, are all supported by peer reviewed scientific research and have been validated according to ISO 17025 and CLIA (Clinical Laboratory Improvement Amendments) requirements, as well as the Laboratories own stringent internal clinical analyst competency program. 

The predisposition test is for medical informational purposes only and you should consult with your physician regarding the test and any healthcare decisions.

While still in the early stages, personalized medicine is steadily emerging as the new healthcare paradigm. In the U.S., the total market for personalized medicine currently is estimated at $232 billion and is projected to grow 11% annually, nearly doubling in size by 2015, to a total of $452 billion, according to PricewaterhouseCoopers' estimates. The core segment of the market -- consisting primarily of diagnostic tests and targeted therapies -- is estimated at $24 billion, and is expected to grow by 10% annually to $42 billion by 2015.

The Company believes that the predictive power of DNA is significant. According to a 2008 report put out by Multimedia Research Group, Inc., based in San Jose, CA., "DNA-based testing is moving into a new phase. Transformational technologies are allowing complex genetic (specific gene) and genomic (large numbers of genes) tests to move from research-only labs into medical and clinical labs that perform tests for individual patients to identify genes associated with specific medical conditions. Progress in this young industry is happening fast and furious."

InoLife was very pleased by the attendance of physicians and medical practitioners that visited their booth. The high level of interest they had for the DNA Predisposition test as well as the DNA based Plavix Metabolizing test was very encouraging. 

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife's products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact Information